News | September 16, 2011

TCT to Showcase Major Research Breakthroughs in Cardiovascular Medicine

September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place Nov. 7-11, 2011 in San Francisco.

The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally. TCT 2011 is expected to be the location of groundbreaking scientific reporting that will modernize care for people with cardiovascular disease and other vascular health issues. 

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Wednesday, Nov. 9, Thursday, Nov. 10, and Friday, Nov. 11.

WEDNESDAY, NOVEMBER 9:

Focus on PCI Pharmacology and Stent Thrombosis I

• ADAPT-DES: A Large-Scale, Prospective, Multicenter Registry Examining the Relationship of Platelet Responsiveness and Stent Thrombosis After [drug-eluting stent] DES Implantation

DESERT: A Large-Scale, Case-Controlled, Multicenter Study Examining the Predictors of Stent Thrombosis

PARIS: A Larger-Scale, Prospective, Multicenter Registry Studying the Patterns of and Reasons for Nonadherence to Antiplatelet Agents in Stented Patients

Focus on PCI Pharmacology and Stent Thrombosis II

RAPID GENE: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in CYP2C19*2 Carriers Identified by Rapid Point-of-Care Genotyping

TRIGGER-PCI: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Clopidogrel-Hyporesponsive Patients with Stable Ischemic Heart Disease Undergoing Percutaneous Coronary Intervention

BRIDGE: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Intravenous Cangrelor in Patients Awaiting Surgery

THURSDAY, NOVEMBER 10

Focus on Transcatheter Aortic Valve Replacement

PARTNER Cohort B Two-Year: A Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Standard Therapy in Patients with Inoperable Aortic Stenosis

PARTNER Cohort A QOL: Quality-of-Life Analysis from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in High-Surgical-Risk Patients with Aortic Stenosis

PARTNER Cohort A CE: Cost-Effectiveness Analysis from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in High-Surgical-Risk Patients with Aortic Stenosis

STACCATO: A Prospective, Randomized Trial of Transapical Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in Low-Surgical-Risk Elderly Patients with Aortic Stenosis

Focus on Primary PCI in STEMI

RIFLE STEACS: A Prospective, Randomized Trial of Radial vs. Femoral Vascular Access in Patients with ST-Segment Elevation Myocardial Infarction

MUSTELA: A Prospective, Randomized Trial of Thrombectomy vs. No Thrombectomy in Patients with ST-Segment Elevation Myocardial Infarction and Thrombus-Rich Lesions

DEB-AMI: A Prospective, Randomized Trial of Paclitaxel-Coated Balloons plus Bare Metal Stents vs. Paclitaxel-Eluting Stents vs. Bare Metal Stents Alone in Patients with ST-Segment Elevation Myocardial Infarction

FRIDAY, NOVEMBER 11

 Focus on Novel Drug-Eluting Stents and Drug-Coated Balloons

EVOLVE: A Prospective, Randomized Trial of Two-Dose Formulations of a Bioabsorbable Polymer-Based Everolimus-Eluting Stent vs. a Durable Polymer-Based Everolimus-Eluting Stent

REMEDEE: A Prospective, Randomized Trial of a Combination Bioabsorbable Polymer-Based Anti-CD34 Antibody Sirolimus-Eluting Stent vs. a Durable Polymer-Based Paclitaxel-Eluting Stent

CRE8: A Prospective, Randomized Trial of a Carbofilm-Coated Stent Eluting Sirolimus from Abluminal Reservoirs vs. a Paclitaxel-Eluting Stent

PEPCAD-DES: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty in Patients with Restenosis of Drug-Eluting Stents

Focus on Optimal PCI

TWENTE: A Prospective, Randomized Trial of Zotarolimus-Eluting Stents and Everolimus-Eluting Stents in an Unselected Patients with Coronary Artery Disease

ROTAXUS: A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Artery Lesions

ADVISE: Validation of a Vasodilator Independent Measure of Coronary Fractional Flow Reserve

Focus on Peripheral Vascular Disease

COBRA: A Prospective, Randomized Trial of Cryoplasty vs. Conventional Balloon Post-dilatation of Nitinol Stents in the Superficial Femoral Artery of Patients with Diabetes Mellitus

PROFI: A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Distal Filter Embolic Protection in Patients Undergoing Carotid Stenting

For more information:  www.tctconference.com/program.html

 

 

Related Content

Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents | May 28, 2020
May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.

News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)
Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.
News | Stents | February 24, 2020
February 24, 2020 — Biotronik announced three-year data from the...
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe.
Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019
Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the global...
The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials